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Contents l ists avai lable at ScienceDirectEditorialOpen the black box; is urine valuable for screening BK virus-associated
nephropathy?BK viruseassociated nephropathy (BKVAN) is one of the
main causes of graft failure after kidney transplantation
[1] and is implicated inmore than 20% of graft failure. Intragraft
inﬂammation and insufﬁcient immune response are regarded
as the main factors of BKVAN. Although the BK polyoma virus
infection is highly prevalent in general population, BKVAN
does not develop in healthy individuals [2]. Primary infection
occurs during childhood and is usually asymptomatic. Then,
BK virus persists in the urinary tract in a latent form. Immuno-
suppressed status makes the latent infection to be an active
illness. In fact, the immunosuppression results in viruria in
30e50% and viremia in 13e22% of kidney transplant recipients
[3]. The advanced stages of BKVAN, decreased renal function,
and accompanying acute rejection are the risk factors for the
progression of BKVAN [4]. Therefore, early detection and
balancing the adequate level of immunosuppression are key
for the prevention of BKVAN, which leads to the prolongation
of graft survival. The current screening guidelines are not vali-
dated in prospective studies, but Kidney Disease: Improving
Global Outcomes clinical practice guidelines include screening
all kidney transplant recipients for BK virus at the following
time points: monthly for the ﬁrst 3e6 months and then every
3 months until the end of the ﬁrst posttransplantation year. Pa-
tients should undergo polymerase chain reactionebased
screening for BK virus every time an unexplained rise in serum
creatinine occurs and after treatment for acute rejection [5].
But the appropriate time point, frequency, and sample type
(blood or urine) remain various according to centers.
In this issue of Kidney Research and Clinical Practice,
Chon et al [6] contributed a manuscript regarding a screening
tool for BKVAN in kidney transplant recipients. They retrospec-
tively reviewed medical records of 368 recipients and analyzed
the signiﬁcance of BK viruria for predicting BK viremia and ne-
phropathy. They claimed that the high-grade BK viruria was
present in one-third of recipients, and the high-grade viruria
imposed the development of viremia and nephropathy with a
50 times likelihood. The sensitivity and speciﬁcity of high-level
viruria (> 25 million copies/mL) for diagnosing BK viremia/ne-
phropathy were 88.6% and 88.0%, respectively. In addition, they
showed that viruria preceded viremia by 7 weeks.
Although kidney transplantation represents the optimal
treatment for patients with end-stage renal disease, the acute
and chronic injuries may induce the eventual decrease of graft
dysfunction. Acute kidney injury, acute rejection, and calcineurinhttp://dx.doi.org/10.1016/j.krcp.2016.08.003
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).inhibitor toxicity are the main differential diagnoses during the
early period after operation. Soon after the period, BKVAN, anti-
body-mediated rejection, and chronic allograft nephropathy
should be listed for differential diagnosis of later allograft
dysfunction. Unfortunately, invasive procedures are necessary
because allograft biopsy is thegoldencriterion fordeﬁnite conﬁr-
mation. Therefore, unlocking the code using a noninvasive
approach may be the way where every clinician wants to stand
on. Among the various human biospecimens, urine is the easiest
and oldest noninvasively accessed source of human biomarkers.
Despite the ambiguity of the original abnormality, renal speci-
ﬁcity of urine may be potentiated by adopting other markers
such as proteinuria and glomerular ﬁltration rate [7]. Unlocking
the code using urine may broaden the concept and the way of
approach for kidney disease. Considering the development of
valuable techniques and understandings, the contribution by
Chonet al [6] is very informative and timely. But there are several
limitations to be resolved. As they stated, a large percentage of
patients with viruria may not develop viremia or nephropathy,
and the lag in viral load reduction on lowering immunosuppres-
sion is not established yet. Furthermore, the cutoff criteria for BK
viruria are still arbitrary depending on centers. However, early
diagnosis using urine polymerase chain reaction may become
more useful when an effective antiviral therapy becomes avail-
able and an adequate measurement may preclude the viremia
before irreversible tissue damage is established.
Finding a needle in a haystack used to be the traditional pro-
cess that clinicians rely on, but understanding the value of bio-
specimens such as urine may expand clinicians' scope. It will
bring us the way of assessing the whole haystack instead of
searching through it.
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